
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical Ltd has recently achieved significant operational milestones, including receiving regulatory approval in Japan for its Alpha DaRT platform, which enhances the prospects for clinical development in the U.S. The company also secured a radioactive material license in New Hampshire and initiated construction of a commercial-scale manufacturing facility, positioning it for future manufacturing of Alpha DaRT beginning in 2026. The favorable cash position further supports its ongoing clinical programs targeting multiple solid tumor types, bolstering the potential for market success and revenue generation.
Bears say
Alpha Tau Medical Ltd reported a significant net loss of $42.6 million in 2025, reflecting ongoing financial challenges and a higher-than-anticipated loss per share of $0.53, which raises concerns about the company's financial sustainability. The company faces multiple risks that could impede its future success, including potential failures in clinical trials, difficulties in securing regulatory approval in the U.S., and challenges related to market penetration and competition for its Alpha DaRT technology. Additionally, there is a looming risk of dilution that may further impact shareholder value, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares